FDA Approves Monjuvi Combination Therapy for Follicular Lymphoma

FDA approves Monjuvi combination therapy for follicular lymphoma

FDA Approves Monjuvi for Treating Relapsed or Refractory Follicular Lymphoma

FDA approves Brukinsa tablet for CLL, certain B-cell lymphomas

The U.S. Food and Drug Administration (FDA) has approved a tablet formulation of Beone Medicines’ Brukinsa (zanubrutinib) — previously marketed by the developer in capsule form — for several types of blood cancer that affect immune B-cells, such as chronic lymphocytic leukemia (CLL) and certain lymphomas. “With this new tablet formulation, we are making treatment simpler and more convenient — an important step forward for patients facing certain…

Behind the FDA Approval: Dr Poh on Tafasitamab in FL

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

FDA Approves Tafasitamab for Follicular Lymphoma

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy.

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma

This is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) and the second indication for Monjuvi.